Clinical trial
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or…
NCT00096031 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00096031 |
|---|---|
| Title | S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer |
| Official title | Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Biological |
| Interventions | cetuximab |
| Enrollment | 63 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2010 |
| First posted | Nov 9, 2004 |
| Last update posted | Sep 26, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: